Neuro-oncology unit

Summary

The Neuro-oncology group is focused in the study of brain tumor treatments and the neurological complications related with cancer and cancer treatments. The group’s aim is to create and reinforce a research network between clinical and preclinical researchers, both within and outside the institution, to provide novel therapeutic options for the patients, improve the diagnostic tools and contribute to increase the knowledge in these fields.

379 Publications

Strategic lines

Assessment of new drugs and new treatment approaches for gliomas and meningiomas (Jordi Bruna, Carles Mesia, Ana Lucas, Carles Majós, Gerard Plans)
Chemotherapy-induced peripheral neuropathies (Jordi Bruna, Roser Velasco)
Cancer and cognition (Marta Simó)
Leptomeningeal metastases (Jordi Bruna)
Survival prognostic factors involved in central nervous system tumours (Noemí Vidal, Jordi Bruna, Carles Majós. Albert Pons)
Prevention and personalised treatment of brain metastases: development of new therapies based on the prevention and prognosis of biomarkers (Carles Mesia, Noemí Vidal, Gerard Plans, Ana Lucas)
Quantitative assessment of advanced MR techniques in clinical neurooncology (Carles Majos, Albert Pons)

Selected Publications

Nadal,E;Rodríguez Abreu,D;Simó,M;Massutí,B;Juan,O;Huidobro,G;López,R et al, Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05), J. Clin. Oncol., 2023;41(28):4478-4485, doi:10.1200/JCO.22.02561
Velasco,R;Argyriou,AA;Marco,C;Mariotto,S;Stradella,A;Hernández,J;Pernas,S et al, Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity., J. Neurol., 2023;270(1):531-537, doi:10.1007/s00415-022-11377-4
Majós,C;Pons Escoda,A;Naval,P;Guell,A;Lucas,A;Vidal,N;Cos,M et al, Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors, Eur. Radiol., 2023;doi:10.1007/s00330-023-10138-9
Alemany,M;Todeschini,FA;Vidal,N;Pons,A;Plans,G;Vilarino,N;Macià,M et al, The impact of health system crises on glioblastoma management and outcomes, Neuro-Oncology, 2023;25(3):609-611, doi:10.1093/neuonc/noac266
Pons Escoda,A;Garcia Ruiz,A;Garcia Hidalgo,C;Gil Solsona,R;Naval Baudin,P;Martin Noguerol,T;Fernandez Coello,A et al, MR dynamic-susceptibility-contrast perfusion metrics in the presurgical discrimination of adult solitary intra-axial cerebellar tumors, Eur. Radiol., 2023;33(12):9120-9129, doi:10.1007/s00330-023-09892-7,

Selected Projects

FIS21056. Comprensión y modulación de los mecanismos de respuesta senescente en la neuropatía inducida por platinos. Instituto de Salud Carlos III (ISCIII). Budget: 165.770€. 2022-2024. PI: Bruna Escuer, Jordi.
21FIS037. Valoración pronóstica de los gliomas cerebrales mediante Espectroscpia por RM (MRS-PROG). Instituto de Salud Carlos III (ISCIII). Budget: 58.080€. 2021-2023. PI: MAJOS TORRO, CARLOS.
19FIS035. Cáncer de pulmón y toxicidad cognitiva: marcadores serológicos y de neuroimagen de disrupción de la barrera hemato-encefálica. Instituto de Salud Carlos III (ISCIII). Budget: 93.170€. 2019-2023. PI: Simó Parra, Marta.
21FIS039. Neurotoxicidad inducida por quimioterapia y estado nutricional: biomarcadores clínicos, séricos, radiológicos y neurofisológicos asociados al desarrollo y la regeneración nerviosa. Instituto de Salud Carlos III (ISCIII). Budget: 93.170€. 2021-2024. PI: VELASCO FARGAS, ROSER.
2022-231-1. Estudio de fase II, multicéntrico, aleatorizado, con doble enmascaramiento, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de ATX01 (Clorhidrato de Amitriptilina tópica al 10 % y al 15 % p/p) en comparación con placebo en pacientes adultos que han sobrevivido a un cáncer y presentan neuropatía periférica inducida por quimioterapia –NPIQ. WORLDWIDE CLINICAL TRIALS, INC. Budget: 58.375,75€. 2022- . PI: Bruna Escuer, Jordi.

More Information

Identification of markers of clinical and neurophysiological predictive risk for developing oxaliplatin-induced neuropathy.
New demonstrations on the efficacy of the new sigma-1 receptor antagonist in preventing acute oxaliplatin-induced neuropathy in a randomised, phase 2 study.
Documentation of longitudinal brain changes associated with prophylactic cranial irradiation and chemotherapy in patients with small-cell lung cancer.
Identification of a common feature in glioblastomas: intrinsic deficiency of the DFF40/CAD endonuclease which affects DNA hydrolysis during caspase-dependent cell death.